trending Market Intelligence /marketintelligence/en/news-insights/trending/Ltn5pkS3Bt71DU6mph18Zw2 content esgSubNav
In This List

VolitionRx acquires epigenetic reagent developer Octamer in €650,000 deal

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


VolitionRx acquires epigenetic reagent developer Octamer in €650,000 deal

VolitionRx Ltd. agreed to acquire Munich-based epigenetic reagent developer Octamer GmbH in a €650,000 cash and share deal.

Singapore-based cancer diagnostic test developer VolitionRx — operating through its unit Belgian Volition SA — is offering 73,000 common shares of Volition and €350,000 cash in exchange for all outstanding shares of Octamer.

The acquisition, expected to close in January 2020, will help secure the supply of the recombinant nucleosome, which is used as a calibrant for Volition's cancer diagnostic test Nu.Q.